- Home
- LBRDA vs MDGL Comparison
LBRDA vs MDGL Comparison
Compare LBRDA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRDA
- MDGL
- Stock Information
- Founded
- LBRDA 2014
- MDGL 2011
- Country
- LBRDA United States
- MDGL United States
- Employees
- LBRDA N/A
- MDGL N/A
- Industry
- LBRDA Cable & Other Pay Television Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- LBRDA Telecommunications
- MDGL Health Care
- Exchange
- LBRDA Nasdaq
- MDGL Nasdaq
- Market Cap
- LBRDA 8.3B
- MDGL 9.6B
- IPO Year
- LBRDA N/A
- MDGL N/A
- Fundamental
- Price
- LBRDA $57.04
- MDGL $429.18
- Analyst Decision
- LBRDA Buy
- MDGL Strong Buy
- Analyst Count
- LBRDA 2
- MDGL 12
- Target Price
- LBRDA $105.00
- MDGL $521.09
- AVG Volume (30 Days)
- LBRDA 76.1K
- MDGL 257.9K
- Earning Date
- LBRDA 11-05-2025
- MDGL 11-04-2025
- Dividend Yield
- LBRDA N/A
- MDGL N/A
- EPS Growth
- LBRDA 36.76
- MDGL N/A
- EPS
- LBRDA 7.58
- MDGL N/A
- Revenue
- LBRDA $1,052,000,000.00
- MDGL $515,547,000.00
- Revenue This Year
- LBRDA $8.37
- MDGL $394.38
- Revenue Next Year
- LBRDA $2.91
- MDGL $64.73
- P/E Ratio
- LBRDA $7.58
- MDGL N/A
- Revenue Growth
- LBRDA 7.24
- MDGL 3421.98
- 52 Week Low
- LBRDA $55.91
- MDGL $210.32
- 52 Week High
- LBRDA $95.95
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- LBRDA 37.70
- MDGL 50.01
- Support Level
- LBRDA $55.94
- MDGL $413.82
- Resistance Level
- LBRDA $56.83
- MDGL $436.79
- Average True Range (ATR)
- LBRDA 1.41
- MDGL 16.49
- MACD
- LBRDA -0.35
- MDGL -2.45
- Stochastic Oscillator
- LBRDA 16.22
- MDGL 41.29
About LBRDA Liberty Broadband Corporation
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.